Cemiplimab is an anti-PD-1 antibody approved by the FDA in September 2018 for the treatment of cutaneous squamous cell carcinoma (cSCC), and in February 2021 for cutaneous basal cell carcinoma (cBCC) and for first-line treatment of NSCLC with PD-L1 expression of ≥50% (47, 48). The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.